Israel Englander’s Acrivon Therapeutics ACRV Stock Holding History

Israel Englander’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-121,524	Closed	-$293K	–	5636
2025 Q4	$293K	Sell	121,524 -63,710	-34%	-$138K	﹤0.01%	5277
2025 Q3	$335K	Sell	185,234 -111,005	-37%	-$156K	﹤0.01%	5291
2025 Q2	$353K	Buy	+296,239	New	+$407K	﹤0.01%	5108
2024 Q4	–	Sell	-39,750	Closed	-$278K	–	5896
2024 Q3	$278K	Buy	+39,750	New	+$313K	﹤0.01%	5244
2024 Q2	–	Sell	-95,497	Closed	-$683K	–	5812
2024 Q1	$683K	Buy	+95,497	New	+$443K	﹤0.01%	4597
2023 Q1	–	Sell	-19,639	Closed	-$226K	–	6296
2022 Q4	$226K	Buy	+19,639	New	+$249K	﹤0.01%	5257

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's ACRV Position: Q1 2026 in Review

Israel Englander sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 121,524 shares — an estimated $293K sold.

Israel Englander first reported a position in ACRV in Q4 2022 and held it in 6 quarters. The position peaked at $683K in Q1 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Israel Englander reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
Israel Englander sold 121,524 Acrivon Therapeutics shares in Q1 2026, an estimated $293K.
Israel Englander first reported a position in Acrivon Therapeutics in Q4 2022 and held it in 6 quarters.
Israel Englander's Acrivon Therapeutics position peaked at $683K in Q1 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.